Jefferies Upgrades Abivax to Buy, Raises Price Target to $158
Jefferies analyst Faisal Khurshid upgrades Abivax (NASDAQ: ABVX ) from Hold to Buy and raises the price target from $108 to $158.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.